KRÜGER Martin
No ORCID on file
· 98 papers in corpus
· active 2002-2005
Frequent coauthors
- MENRAD Andreas 98
- THIERAUCH Karl-Heinz 98
- HABEREY Martin 98
- HUTH Andreas 98
- ERNST Alexander 70
- ZORN Ludwig 28
- HESS-STUMP Holger 28
- INCE Stuart 28
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …